The Fourth Episode This Year: Recurrent Bacterial Vaginosis in a 29-Year-Old and the 2025 Trial That Brought Her Partner Into the Treatment Plan
[Student Name]
University of Phoenix
NRP/563: Management of Women's Health Issues
Week 6 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Ms. D., a 29-year-old graphic designer, has had vaginal discharge with a fishy odor for five days, her fourth similar episode in 12 months. Each previous episode was treated with metronidazole, with relief for a few weeks. She has had the same male partner for two years, uses condoms inconsistently and a copper IUD for contraception. She is frustrated and embarrassed. This paper describes the evaluation and plan.
Confirming the Diagnosis
Bacterial vaginosis is a shift in vaginal flora from protective lactobacilli to a mix of anaerobic bacteria, including Gardnerella and others. The CDC guideline describes clinical diagnosis by Amsel criteria, requiring three of four findings, or Gram stain, and notes that molecular tests are also available (Workowski et al., 2021). On examination, Ms. D. has a thin, gray discharge coating the vaginal walls, pH 5.5, a positive whiff test and clue cells on saline microscopy. She meets all four criteria. No trichomonads or yeast are seen. I also test for chlamydia and gonorrhea, since sexually transmitted infections can coexist.
Standard Treatment
The CDC recommends oral metronidazole 500 mg twice daily for seven days, metronidazole gel intravaginally for five days or clindamycin cream intravaginally for seven days (Workowski et al., 2021). I prescribe oral metronidazole for seven days and advise avoiding alcohol during treatment and for a day after.
Why It Keeps Coming Back
Bradshaw et al. (2006) followed women treated for bacterial vaginosis and found that 58% had a recurrence within 12 months. Factors associated with recurrence included a past history of bacterial vaginosis, having a regular sex partner throughout the study and having female partners, while hormonal contraception was associated with lower recurrence. The authors concluded that current treatment does not prevent recurrence in most women and that the associations suggest a role for sexual transmission.
Treating her again and again while her partner stayed untreated may have been treating half of the problem.
The New Evidence
Vodstrcil et al. (2025) randomly assigned couples, in which a woman had bacterial vaginosis and a regular male partner, to treatment of the woman alone or treatment of both, with the male partner receiving oral metronidazole and topical clindamycin cream applied to the penile skin for seven days. The trial was stopped early because recurrence within 12 weeks was 35% in the partner-treatment group compared with 63% in the woman-only group.
Applying It to Ms. D.
Ms. D. has a regular male partner and recurrent disease, the situation studied in the trial. After discussing the evidence, she wants her partner treated. I explain the regimen and ask whether he would come in or see his own clinician; he agrees to an appointment the same week. Where permitted, some clinicians prescribe for partners directly; our clinic sees partners as patients.
Other Contributing Factors
Her copper IUD may be associated with a higher risk of bacterial vaginosis in some studies, while hormonal methods appear protective. If recurrences continue, we can discuss switching to a hormonal IUD. Douching, which she does occasionally after her period, disrupts vaginal flora; I recommend stopping. Consistent condom use may reduce recurrence.
How the Partner Treatment Works
The trial's partner regimen combined oral metronidazole with clindamycin cream applied to the penile skin, targeting bacteria that may live on the skin and in the urethra and be passed back after the woman is treated (Vodstrcil et al., 2025). The combination reflects the idea that the male partner can harbor the same bacterial community. Adherence by the partner matters, so I give Ms. D. written instructions to share.
What the Trial Did Not Show
The trial followed couples for 12 weeks, included only monogamous heterosexual couples and was stopped early, which can exaggerate effects. Longer-term benefit and application to other relationships are uncertain. The CDC guideline, written before the trial, did not recommend routine partner treatment (Workowski et al., 2021), so this recommendation represents evolving practice, which I explain to Ms. D.
Side Effects
Metronidazole can cause a metallic taste, nausea and, with alcohol, a severe reaction with flushing and vomiting. Clindamycin cream can weaken latex condoms for several days, so they should not be relied on for contraception or infection prevention during and just after treatment.
Suppressive Therapy
For women with frequent recurrences, the CDC guideline describes suppressive therapy with twice-weekly metronidazole gel for four to six months after completing treatment (Workowski et al., 2021). I offer this as an option if she has another recurrence despite partner treatment.
Why It Matters
Bacterial vaginosis is not just a nuisance. It is associated with increased risk of acquiring sexually transmitted infections, including HIV, and of pelvic inflammatory disease and, in pregnancy, preterm birth. Treating recurrence is part of protecting her reproductive health.
Reassurance
Ms. D. worried that the infection meant her partner was unfaithful. I explain that bacterial vaginosis is not a classic sexually transmitted infection, that it occurs in women in long-term monogamous relationships and that the partner's role likely reflects shared bacteria, not infidelity.
When to Consider Other Diagnoses
If symptoms persist despite treatment or recur quickly with atypical features, I will consider other causes, such as trichomoniasis, which can be detected by molecular testing and requires partner treatment, or cytolytic vaginosis and desquamative inflammatory vaginitis, which are less common. A vaginal culture or molecular panel can help clarify.
Probiotics
Ms. D. asks about probiotics. Evidence that oral or vaginal probiotics prevent recurrence is limited and inconsistent. They are unlikely to cause harm, and she may try them, but they should not replace the treatments with stronger evidence.
Sex During Treatment
I advise avoiding intercourse, or using condoms consistently after clindamycin treatment is complete, until both she and her partner finish treatment, to reduce the chance of passing the bacteria back and forth.
Her Frustration
Four episodes in a year had worn down Ms. D.'s confidence. I acknowledged that recurrence is common and not her fault, and explained that the new plan targets causes the previous treatments did not reach, which gives this course a better chance of lasting.
Documentation
The note records the Amsel findings, the regimen, the partner referral and the rationale drawn from the 2025 trial, so that the next clinician understands why her partner was treated.
Follow-Up
A test of cure is not routinely needed if symptoms resolve, but she should return if symptoms recur, and we will reassess her contraception and consider suppressive therapy.
Conclusion
Ms. D.'s fourth episode of bacterial vaginosis was confirmed by Amsel criteria and treated with the CDC-recommended regimen. Cohort data show that most women experience recurrence, and a 2025 randomized trial found that treating male partners cut recurrence nearly in half. Adding partner treatment, stopping douching, considering a hormonal contraceptive and offering suppressive therapy if needed address the causes of her recurrence, not only the current episode.
References
Bradshaw, C. S., Morton, A. N., Hocking, J., Garland, S. M., Morris, M. B., Moss, L. M., Horvath, L. B., Kuzevska, I., & Fairley, C. K. (2006). High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. The Journal of Infectious Diseases, 193(11), 1478-1486. https://doi.org/10.1086/503780
Vodstrcil, L. A., Plummer, E. L., Fairley, C. K., Hocking, J. S., Law, M. G., Petoumenos, K., Bateson, D., Murray, G. L., Donovan, B., Chow, E. P. F., Chen, M. Y., Kaldor, J., & Bradshaw, C. S. (2025). Male-partner treatment to prevent recurrence of bacterial vaginosis. New England Journal of Medicine, 392(10), 947-957. https://doi.org/10.1056/NEJMoa2405404
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187. https://doi.org/10.15585/mmwr.rr7004a1
How this NRP 563 Week 6 example is structured
The NRP/563 Week 6 work usually addresses gynecologic conditions such as vaginitis and sexually transmitted infections. This paper covers diagnosis, standard treatment, why standard treatment often fails and how new evidence changes the plan for recurrent disease. Students search this week as NRP 563 Week 6, NRP563 Wk 6 or NRP/563 Wk 6; all three are the same assignment.
NRP/563 Week 6 questions, answered
What does NRP/563 Week 6 usually ask for?
Many sections present a gynecologic infection, such as vaginitis or a sexually transmitted infection, and ask for diagnosis, treatment and partner management.
How is bacterial vaginosis diagnosed in the office?
Commonly with Amsel criteria, at least three of four: thin, homogeneous discharge; vaginal pH above 4.5; a fishy odor with potassium hydroxide; and clue cells on microscopy. Gram stain or molecular tests are alternatives.
Should partners of women with bacterial vaginosis be treated?
CDC guidelines have not recommended routine partner treatment, but a 2025 randomized trial found that treating male partners reduced recurrence, and practice is evolving.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.